{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T07:55:26Z","timestamp":1762761326457},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1097\/md.0000000000001966","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T12:51:12Z","timestamp":1447764672000},"page":"e1966","source":"Crossref","is-referenced-by-count":22,"title":["Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia"],"prefix":"10.1097","volume":"94","author":[{"given":"Quentin","family":"Maestraggi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9gol\u00e8ne","family":"Toquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Kianmanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Servettaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210309","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2006.12.008","article-title":"Liver involvement in hereditary hemorrhagic telangiectasia (HHT).","volume":"46","author":"Garcia-Tsao","year":"2007","journal-title":"J Hepatol"},{"key":"R2-10-20210309","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1007\/s10620-011-1585-2","article-title":"Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia.","volume":"56","author":"Buscarini","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R3-10-20210309","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jhep.2006.01.009","article-title":"Ischemic cholangiopathy.","volume":"44","author":"Deltenre","year":"2006","journal-title":"J Hepatol"},{"key":"R4-10-20210309","first-page":"15","article-title":"Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density.","volume":"15","author":"Sadick","year":"2005","journal-title":"Int J Mol Med"},{"key":"R5-10-20210309","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1012774","article-title":"Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.","volume":"364","author":"Brinkerhoff","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-10-20210309","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00277-010-1063-5","article-title":"Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia.","volume":"90","author":"Fodstad","year":"2011","journal-title":"Ann Hematol"},{"key":"R7-10-20210309","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MCG.0b013e3182688d49","article-title":"Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.","volume":"47","author":"Lupu","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"R8-10-20210309","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jhep.2013.02.006","article-title":"Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab.","volume":"59","author":"Vlachou","year":"2013","journal-title":"J Hepatol"},{"key":"R9-10-20210309","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"key":"R10-10-20210309","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1024\/0301-1526\/a000253","article-title":"Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).","volume":"42","author":"Chavan","year":"2013","journal-title":"Vasa"},{"key":"R11-10-20210309","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/lt.21417","article-title":"Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.","volume":"14","author":"Mitchell","year":"2008","journal-title":"Liver Transpl"},{"key":"R12-10-20210309","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"R13-10-20210309","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2007-1018558","article-title":"Laparascopic findings in hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease).","volume":"16","author":"Solis-Herruzo","year":"1984","journal-title":"Endoscopy"},{"key":"R14-10-20210309","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.3748\/wjg.v16.i48.6119","article-title":"High prevalence of non-alcoholic fatty liver in patients with idiopathic venous thromboembolism.","volume":"16","author":"Di Minno","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R15-10-20210309","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3899\/jrheum.131345","article-title":"Increased risk of deep vein thrombosis and pulmonary embolism in Sjogren syndrome: a nationwide cohort study.","volume":"41","author":"Chung","year":"2014","journal-title":"J Rheumatol"},{"key":"R16-10-20210309","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5045\/br.2014.49.3.192","article-title":"Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab.","volume":"49","author":"Wee","year":"2014","journal-title":"Blood Res"},{"key":"R17-10-20210309","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","article-title":"Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.","volume":"5","author":"Thompson","year":"2014","journal-title":"Allergy Rhinol (Providence)"},{"key":"R18-10-20210309","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/mabs.28025","article-title":"ELLIPSE study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.","volume":"6","author":"Dupuis-Girod","year":"2014","journal-title":"MAbs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:53:33Z","timestamp":1620960813000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201511170-00010"}},"subtitle":["Be Cautious A Case Report"],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":18,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001966","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}